Histone deacetylases (HDACs) play an important role in regulating the expression of genes
involved in tumorigenesis and tumor maintenance, and hence they have been considered …

Over the past two decades, the natural history of multiple myeloma (MM) has evolved
dramatically, owing primarily to novel agents targeting MM in the bone marrow …

Dear Editor, Multiple myeloma (MM) is a malignant plasma cancer that grows in the bone
marrow and migrates through the bloodstream. Fifty-eight percent of MM patients exhibit the …

Our recent studies have shown that cross‐talk between histone deacetylase 5 (HDAC5) and
lysine‐specific demethylase 1 (LSD1) facilitates breast cancer progression. In this work, we …

Histone deacetylases (HDACs) deacetylate the lysine residues of both histones and non-
histone proteins. Histone acetylation results in a loose local chromatin structure that …

Despite administration of novel therapies, multiple myeloma (MM) remains incurable with
resistance to drugs leading to relapse in most patients. Thus, it is critical to understand the …

Acute leukemia is a highly heterogeneous disease; therefore, combination therapy is
commonly used for patient treatment. Drug–drug interaction is a major concern of combined …

Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to
the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor …

Fast clearance, metabolism and systemic toxicity are major limits for the clinical use of anti-
cancer drugs. Histone deacetylase inhibitors (HDACi) present these defects despite …

Multiple myeloma is the second most common malignant hematologic malignancy which
evolved different strategies for immune escape from the host immune surveillance and drug …